An independent panel of US medical experts voted Monday to recommend Eli Lilly’s experimental Alzheimer’s drug, meaning there could soon be another treatment option available to patients with the devastating brain disorder. Donanemab was found in a trial carried out last year to slow cognitive decline in the early stages of the disease—but there was also a high rate of side effects, including deaths. The Food and Drug Administration (FDA) in March pushed back a planned meeting of experts to evaluate the safety of the intravenously-injected antibody. It normally follows Read More